Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $578.65, for a total value of $5,497,175.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $23,442,847.45. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Stock Down 0.6%

UTHR stock traded down $3.75 during mid-day trading on Thursday, reaching $575.79. The company had a trading volume of 349,504 shares, compared to its average volume of 482,157. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market capitalization of $24.44 billion, a P/E ratio of 21.25, a P/E/G ratio of 1.84 and a beta of 0.60. The stock’s 50-day simple moving average is $554.96 and its two-hundred day simple moving average is $505.54.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the business earned $6.63 EPS. On average, research analysts forecast that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on UTHR shares. Royal Bank Of Canada reduced their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. AE Wealth Management LLC grew its stake in shares of United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC lifted its stake in United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Optimize Financial Inc bought a new stake in United Therapeutics during the third quarter worth approximately $444,000. Tobam boosted its holdings in United Therapeutics by 183.9% during the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after buying an additional 4,953 shares in the last quarter. Finally, Perpetual Ltd acquired a new position in United Therapeutics in the fourth quarter worth approximately $1,059,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.